CD8A and neoplasm: The authors proposed a model in which tumor-derived TGF-β promotes the upregulation of miR-491 in CD8 T cells which, in turn, decreases the expression of Bcl-xL, TCF-1 and CDK4 and dampens their antitumoral function [66].